Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here PRINCETON, NJ, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet...

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Provides interested parties the ability to ask questions and submit...